Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 17, 2018

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2026

Conditions

Sarcoma

Interventions

DRUG

nivolumab

240 mg every 2 weeks

DRUG

ipilimumab

1 mg/kg every 6 weeks

Trial Locations (1)

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester

All Listed Sponsors

lead

University of Rochester

OTHER